Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Swartz probably increases stock sales on each license announcement

Do you know that he has not done so? I don't know about you and your situation but this stock hasn't held up very well when you consider a 90% loss in value in two years. We are not zero so I guess there is a bright side. I'm not even sure how one would respond to your last statement/guess/assumption/theory. Your thought process based on the decreasing amount of shares traded for each of the announced licenses does not seem to be supported. My thought is that Swartz rode this horse for a couple hundred million and could care less about a company who's stock is $0.20 and that doesn't appear to be in a position to have recurring revenues from a steady licensing program. My opinion and guess just like yours.

Share
New Message
Please login to post a reply